Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2015-000371-26-ES
EUCTR2015-000371-26-ESActive, not recruitingNot Applicable

A phase 2/3, multicenter, randomized, double-blinded, placebo-controlled, repeatdose, dose-comparison study to evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of olipudase alfa in patients with acid sphingomyelinase deficiency - ASCEND

Genzyme Corporation0 sites35 target enrollmentStarted: October 5, 2015Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Enrollment
35
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •The patient is willing and able to provide signed written informed consent.
  • •The patient is male or female aged 18 years or older.
  • •The patient has documented deficiency of acid sphingomyelinase as measured in peripheral leukocytes, cultured fibroblasts, or lymphocytes; and a clinical diagnosis consistent with Niemann-Pick disease type B (NPD B).
  • •The patient has diffuse capacity of the lung for carbon monoxide ?70% of the predicted normal value.
  • •The patient has a spleen volume ?6 multiples of normal (MN) measured by MRI; patients who have had partial splenectomy will be allowed if the procedure was performed ?1 year before screening/baseline and the residual spleen volume is ?6 MN.
  • •Female patients of childbearing potential must have a negative serum pregnancy test for beta-human chorionic gonadotropin (?-HCG).
  • •Female patients of childbearing potential and male patients must be willing to practice true abstinence in line with their preferred and usual lifestyle, or use 2 acceptable effective methods of contraception.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 34
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 1

Exclusion Criteria

  • •The patient has received an investigational drug within 30 days before study enrollment.
  • •The patient has a medical condition, including significant intercurrent illness; significant cardiac disease (eg, clinically significant arrhythmia, moderate or severe pulmonary hypertension or valvular dysfunction, or <40% left ventricular ejection fraction by echocardiogram); active hepatitis B or hepatitis C, or infection with human immunodeficiency virus (HIV); cirrhosis (as determined by clinical evaluation or liver biopsy); malignancy diagnosed within the past 5 years (other than basal cell carcinoma), or any other extenuating circumstance that may significantly interfere with study compliance, including all prescribed evaluations and follow-up activities.
  • •The patient has a platelet count <60,000/?L (based on the average of 2 samples obtained at least 12 hours but no longer than 24 hours apart).
  • •The patient has an international normalized ratio (INR) >1.5.
  • •The patient has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >250 IU/L or total bilirubin >1.5 mg/dL (except for patients with Gilbert's syndrome).
  • •The patient has had a major organ transplant (eg, bone marrow or liver).
  • •The patient is scheduled during the study for in-patient hospitalization including elective surgery and excluding the liver biopsies required per protocol.
  • •The patient, in the opinion of the investigator, is unable to adhere to the requirements of the study.
  • •The patient is unwilling or unable to abstain from the use of alcohol for 1 day before and 3 days after each study drug infusion. Testing for blood alcohol levels will not be required.
  • •The patient is unwilling or unable to avoid 10 days before and 3 days after the protocol scheduled liver biopsies that are required at screening/baseline and at week 52, the use of medications or herbal supplements that are potentially hepatotoxic (e.g., 3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitors, erythromycin, valproic acid, anti-depressants, kava, echinacea) and/or may cause or prolong bleeding (e.g., anti-coagulants, ibuprofen, aspirin, garlic supplements, ginkgo, ginseng).
  • •The patient requires medications that may decrease olipudase alfa activity (e.g., fluoxetine, chlorpromazine, tricyclic antidepressants [e.g., imipramine, or desipramine]).
  • •The patient requires use of invasive ventilatory support.
  • •The patient requires use of noninvasive ventilator support while awake for longer than 12 hours daily.
  • •The patient is breast-feeding.

Investigators

Similar Trials

Recruiting
Phase 2
A phase 2/3, multicenter, randomized, double-blinded, placebo-controlled, repeatdose study to evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of olipudase alfa in patients with acid sphingomyelinase deficiencyNieman-Pick syndrome10027424
NL-OMON54584Sanofi B.V.5
Active, not recruiting
Phase 1
A phase 2/3, multicenter, randomized, double-blind study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of oral ozanimod (RPC1063) in pediatric subjects with moderately to severely active ulcerative colitis with an inadequate response to conventional therapy.Moderately to Severely Active Ulcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 10017947 - Gastrointestinal disorders
EUCTR2021-002308-11-PLCelgene International II Sàrl120
Recruiting
Phase 1
A phase 2/3, multicenter, randomized, double-blind study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of oral ozanimod (RPC1063) in pediatric subjects with moderately to severely active ulcerative colitis with an inadequate response to conventional therapy.Moderately to Severely Active Ulcerative ColitisMedDRA version: 20.1Level: LLTClassification code: 10045365Term: Ulcerative colitis Class: 10017947
CTIS2023-509248-86-00Celgene International II S.a.r.l.128
Active, not recruiting
Phase 1
A phase 2/3, multicenter, randomized, double-blind study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of oral ozanimod (RPC1063) in pediatric subjects with moderately to severely active ulcerative colitis with an inadequate response to conventional therapy.Moderately to Severely Active Ulcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856
EUCTR2021-002308-11-ESCelgene International II Sàrl120
Active, not recruiting
Phase 1
Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients with Acid Sphingomyelinase DeficiencyPatients with acid sphingomyelinase deficiency (Niemann-Pick Type B disease)MedDRA version: 20.1Level: LLTClassification code 10041515Term: Sphingomyelin lipidosisSystem Organ Class: 100000004850
EUCTR2015-000371-26-ITGENZYME CORPORATIO35